<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: The Future of Specialty Drugs</title>
	<atom:link href="http://www.rxtimes.com/the-future-of-specialty-drugs/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.rxtimes.com/the-future-of-specialty-drugs/</link>
	<description>Pharmacy news, jobs, continuing education, community and more.</description>
	<lastBuildDate>Tue, 08 Nov 2011 18:51:25 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
	<item>
		<title>By: Pharmaceutical Consulting</title>
		<link>http://www.rxtimes.com/the-future-of-specialty-drugs/#comment-3487</link>
		<dc:creator>Pharmaceutical Consulting</dc:creator>
		<pubDate>Thu, 25 Feb 2010 15:33:04 +0000</pubDate>
		<guid isPermaLink="false">http://www.rxtimes.com/?p=4288#comment-3487</guid>
		<description>But when will we see results? The ongoing study of molecular biology for specialty drugs, in theory, has a great deal of potential. It is the problem of translating that potential into cures for chronic diseases. I know I sound impatient, but so much time and money is invested in molecular biology and results for specialty drugs have been sub-par, and that&#039;s putting it lightly.</description>
		<content:encoded><![CDATA[<p>But when will we see results? The ongoing study of molecular biology for specialty drugs, in theory, has a great deal of potential. It is the problem of translating that potential into cures for chronic diseases. I know I sound impatient, but so much time and money is invested in molecular biology and results for specialty drugs have been sub-par, and that&#8217;s putting it lightly.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

